Pfizer Vaccines Do Not Work Well After 6 Months Study Reveals

Image Source: Reuters
  • The effectiveness of the Pfizer Inc (PFE.N)/BioNTech SE vaccine in preventing infection by the coronavirus drops to 47% from 88% six months after the second dose.
  • It showed that the vaccine’s effectiveness in preventing hospitalization and death remained high at 90% for at least 6 months, even against the highly contagious Delta variant of the coronavirus.

Pfizer Vaccines Do Not Work Well After 6 Months Study Reveals

This might seem scary to know in the midst of a life-threatening pandemic but here goes nothing! Apparently, the effectiveness of the Pfizer Inc (PFE.N)/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose. This was revealed according to data published on Monday that U.S. health agencies considered when deciding on the need for booster shots.

This data was published in The Lancet Medical Journal and had been previously released in August ahead of peer review. Delving deeper into the analysis, it showed that the vaccine’s effectiveness in preventing hospitalization and death remained high at 90% for at least 6 months, even against the highly contagious Delta variant of the coronavirus.

However, the data suggests that the drop is due to waning efficacy, rather than more contagious variants, researchers said. The researchers from Pfizer and Kaiser Permanente have studied electronic health records of roughly 3.4 million people who were members of Kaiser Permanente Southern California between December 2020, when the vaccine first became available and on August of 2021.

Luis Jodar, senior vice president and chief medical officer at Pfizer vaccines said,"Our variant-specific analysis clearly shows that the (Pfizer/BioNTech) vaccine is effective against all current variants of concern, including Delta."

However, despite this scare caused by the analysis, a potential limitation of the study was a lack of data on adherence to masking guidelines and occupations in the study population, which could have affected the frequency of testing and the likelihood of exposure to the virus.

The vaccine's effectiveness against the Delta variant was 93% after the first month, declining to 53% after four months. Against the other coronavirus variants, however, efficacy declined to 67% from 97%.

Image Source: Marketplace

Study leader Sara Tartof with Kaiser Permanente Southern California's Department of Research & Evaluation chimed in claiming, “To us, that suggests Delta is not an escape variant that is completely evading vaccine protection. If it was, we would probably not have seen high protection after vaccination, because vaccination would not be working in that case. It would start low, and stay low."

In the same cocoon of thoughts, testing for variants is more likely to fail in vaccinated individuals, which could lead to overestimation of variant-specific effectiveness in the study, the authors cautioned.

For some background information, the U.S. Food and Drug Administration has authorized the use of a booster dose of the Pfizer/BioNTech vaccine for older adults and some Americans at high risk of getting infected. On a separate note, scientists have called for more data on whether boosters should be recommended for all.

Total
6
Shares
Previous Post

Singapore To Open Borders To Malaysia Despite Covid Spike

Next Post

Fears Of Covid Outbreak Once Melaka Proceeds For Elections

Related Posts
Total
6
Share